Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atomoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.97 |
| ▸ | HTR2A | P28223 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 2/20 | 0.97 |
| ▸ | HRH1 | P35367 | 2/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.97 |
| ▸ | DRD3 | P35462 | 2/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.97 |
| ▸ | HTR2B | P41595 | 2/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.97 |
| ▸ | KLF10 | Q13118 | 2/20 | 0.97 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atomoxetine SCHEMBL2206798 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL649168 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL1560986 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL122111 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL627231 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL5783906 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29440242 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL341802 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL12047445 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL2209541 | 0.98 | SLC6A4 (1.00) | SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-3402812-B1 | MODULATORS OF ZINC ACTIVATED CATION CHANNEL | DIGNITY HEALTH (US) | 2024-03-27 | — | — | EP | claimed |
| US-11903951-B2 | Nasal pharmaceutical compositions with a porous excipient | M et P Pharma AG (CH) | 2024-02-20 | — | — | US | claimed |
| CN-116635013-A | Orally dispersible powder composition | 生物制药协同效应有限公司 | 2023-08-22 | — | — | CN | claimed |
| US-20230140798-A1 | SYNTHETIC PEPTIDES DIRECTED AGAINST THE METABOTROPIC GLUTAMATE RECEPTOR 5 | LACTOCORE INC (US) | 2023-05-04 | — | — | US | claimed |
| EP-4135741-A1 | SYNTHETIC PEPTIDES FOR MODULATING THE METABOTROPIC GLUTAMATE RECEPTOR 5 | Lactocore, Inc. (US) | 2023-02-22 | — | — | EP | claimed |
| US-20260115163-A1 | NOVEL TREATMENTS | 3Z EHF (IS) | 2026-04-30 | — | — | US | disclosed |
| EP-4654949-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | Hyloris Developments SA (BE) | 2025-12-03 | — | — | EP | disclosed |
| US-20250345436-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | HYLORIS DEV SA (BE) | 2025-11-13 | — | — | US | disclosed |
| CN-115561358-B | Method for detecting impurity B and impurity C in tomoxetine hydrochloride | 广西维威制药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025093748-A1 | USE OF A CALCIUM CHANNEL BLOCKER IN THE TREATMENT OF ADHD | 3Z PHARMACEUTICALS (IS) | 2025-05-08 | — | — | WO | disclosed |
| EP-4284356-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER | 3Z EHF (IS) | 2025-04-02 | — | — | EP | disclosed |
| CN-119595799-A | Reversed-phase high performance liquid chromatography for one-test-multiple-evaluation detection of tomoxetine hydrochloride oral dissolved impurities C, D, E | 重庆希尔安药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20220241222-A1 | ATOMOXETINE HYDROCHLORIDE EXTENDED RELEASE COMPOSITIONS AND METHODS OF USE | CELISTA PHARMACEUTICALS LLC | 2022-08-04 | — | — | US | disclosed |
| WO-2022162199-A2 | NOVEL TREATMENTS | 3Z EHF (IS) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022155162-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) (US) | 2022-07-21 | — | — | WO | disclosed |
| CN-114728011-A | Preparations comprising steroid dimers and uses thereof in therapeutic agent delivery | 波纹疗法公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022124243-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING SAME | 東和薬品株式会社 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022101435-A1 | NOVEL TREATMENTS OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | 3Z EHF (IS) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345436-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | TAS2R5, TAS2R10, TAS2R50 | SLC6A2 20/4885SLC6A4 12/4885CYP1A2 326/4885 |
| US-20260115163-A1 | NOVEL TREATMENTS | SLC6A2, SLC6A3, ACE | SLC6A2 1/4885SLC6A4 7/4885CYP1A2 146/4885 |
| US-20220241222-A1 | ATOMOXETINE HYDROCHLORIDE EXTENDED RELEASE COMPOSITIONS AND METHODS OF USE | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885SLC6A4 2/4885CYP1A2 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.